Back to Search Start Over

Inducible Sbdsdeletion impairs bone marrow niche capacity to engraft donor bone marrow after transplantation

Authors :
Zha, Ji
Kunselman, Lori K.
Xie, Hongbo M.
Ennis, Brian
Shah, Yash B.
Qin, Xia
Fan, Jian-Meng
Babushok, Daria V.
Olson, Timothy S.
Source :
Blood Advances; January 2022, Vol. 6 Issue: 1 p108-120, 13p
Publication Year :
2022

Abstract

Bone marrow (BM) niche-derived signals are critical for facilitating engraftment after hematopoietic stem cell (HSC) transplantation (HSCT). HSCT is required for restoration of hematopoiesis in patients with inherited BM failure syndromes (iBMFSs). Shwachman-Diamond syndrome (SDS) is a rare iBMFS associated with mutations in SBDS. Previous studies have demonstrated that SBDS deficiency in osteolineage niche cells causes BM dysfunction that promotes leukemia development. However, it is unknown whether BM niche defects caused by SBDS deficiency also impair efficient engraftment of healthy donor HSC after HSCT, a hypothesis that could explain morbidity noted after clinical HSCT for patients with SDS. Here, we report a mouse model with inducible Sbdsdeletion in hematopoietic and osteolineage cells. Primary and secondary BM transplantation (BMT) studies demonstrated that SBDS deficiency within BM niches caused poor donor hematopoietic recovery and specifically poor HSC engraftment after myeloablative BMT. We have also identified multiple molecular and cellular defects within niche populations that are driven by SBDS deficiency and are accentuated by or develop specifically after myeloablative conditioning. These abnormalities include altered frequencies of multiple niche cell subsets, including mesenchymal lineage cells, macrophages, and endothelial cells; disruption of growth factor signaling, chemokine pathway activation, and adhesion molecule expression; and p53 pathway activation and signals involved in cell cycle arrest. Taken together, this study demonstrates that SBDS deficiency profoundly impacts recipient hematopoietic niche function in the setting of HSCT, suggesting that novel therapeutic strategies targeting host niches could improve clinical HSCT outcomes for patients with SDS.

Details

Language :
English
ISSN :
24739529 and 24739537
Volume :
6
Issue :
1
Database :
Supplemental Index
Journal :
Blood Advances
Publication Type :
Periodical
Accession number :
ejs58031812
Full Text :
https://doi.org/10.1182/bloodadvances.2021004640